ENTPD2 and cancer: However, for high-risk patients, FCN2 loses its readership, and is heavily regulated by PTGES2 and ENTPD2. In the meantime, PTGES2 activates the ENDOG gene implicated in cancer, aging, and neurodegenerative diseases [22] and ENTPD2 activates the ZNF219 gene as a member of the Sox9-assembled transcriptional factory participating in chondrocyte differentiation [23].